Cancer Organoids as reliable disease models to drive clinical development of novel therapies

被引：2

作者：

Giovanni Blandino ^{[1
]}

Ronit Satchi-Fainaro ^{[2
]}

Ingeborg Tinhofer ^{[3
]}

Giovanni Tonon ^{[4
]}

Sarah C. Heilshorn ^{[5
]}

Yong-Jun Kwon ^{[6
]}

Ana Pestana ^{[3
]}

Carlotta Frascolla ^{[1
]}

Luca Pompili ^{[1
]}

Aurora Puce ^{[7
]}

Sara Iachettini ^{[1
]}

Annalisa Tocci ^{[8
]}

Sofia Karkampouna ^{[9
]}

Marianna Kruithof-de Julio ^{[9
]}

Piera Tocci ^{[10
]}

Nicla Porciello ^{[8
]}

Klizia Maccaroni ^{[7
]}

Daniela Rutigliano ^{[1
]}

Xiling Shen ^{[11
]}

Gennaro Ciliberto ^{[12
]}

机构：

[1] IRCCS Regina Elena National Cancer Institute,Translational Research Unit

[2] Tel Aviv University,Deapartment of Physiology and Pharmacology

[3] Charité University Medicin,Department of Radiooncology and Radiotherapy

[4] IRCCS San Raffaele Scientific Institute,Center of Omics Sciences

[5] Stanford University,Department of Materials Science and Engineering

[6] Luxembourg Institute of Health,Cellular Network and Molecular Therapeutic Target Unit

[7] IRCCS Regina Elena National Cancer Institute,Tumor of Immunology and Immunotherapy Unit

[8] IRCCS Regina Elena National Cancer Institute,Department for BioMedical Research

[9] University of Bern,Unit of Preclinical Models and New Therapeutic Agents

[10] IRCCS Regina Elena National Cancer Institute,GI Medical Oncology

[11] MD Anderson Cancer Center,Scientific Direction

[12] Terasaki Institute of Biomedical Innovation,undefined

[13] IRCCS Regina Elena National Cancer Institute,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 43卷 / 1期

关键词：

Organoid; Precision medicine; Patient-derived 3D culture model; Targeted therapy; Preclinical models; Cancer spheroid;

D O I：

10.1186/s13046-024-03258-7

中图分类号：

学科分类号：

摘要：

On September 23–24 (2024) the 6th Workshop IRE on Translational Oncology, titled “Cancer Organoids as Reliable Disease Models to Drive Clinical Development of Novel Therapies,” took place at the IRCCS Regina Elena Cancer Institute in Rome. This prominent international conference focused on tumor organoids, bringing together leading experts from around the world.

引用

共 50 条

[21] Leveraging synthetic lethality for the development of novel cancer therapies
Briggs, Kimberly
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (12)
[22] Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, Masako
Nagano, Tatsuya
Nishimura, Yoshihiro
MOLECULES, 2020, 25 (17):
[23] Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, Xingshu
Lovell, Jonathan F.
Yoon, Juyoung
Chen, Xiaoyuan
NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (11) : 657 - 674
[24] Clinical development and potential of photothermal and photodynamic therapies for cancer
Xingshu Li
Jonathan F. Lovell
Juyoung Yoon
Xiaoyuan Chen
Nature Reviews Clinical Oncology, 2020, 17 : 657 - 674
[25] Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to
Renee Brady
Heiko Enderling
Bulletin of Mathematical Biology, 2019, 81 : 3722 - 3731
[26] Clinical development of cell therapies for cancer: The regulators' perspective
Exley, Andrew R.
Rantell, Khadija
McBlane, James
EUROPEAN JOURNAL OF CANCER, 2020, 138 : 41 - 53
[27] Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to
Brady, Renee
Enderling, Heiko
BULLETIN OF MATHEMATICAL BIOLOGY, 2019, 81 (10) : 3722 - 3731
[28] Targeted Therapies for Lung Cancer Clinical Experience and Novel Agents
Larsen, Jill E.
Cascone, Tina
Gerber, David E.
Heymach, John V.
Minna, John D.
CANCER JOURNAL, 2011, 17 (06): : 512 - 527
[29] Development of novel therapies for Huntington's disease: hope and challenge
Qin, ZH
Wang, J
Gu, ZL
ACTA PHARMACOLOGICA SINICA, 2005, 26 (02) : 129 - 142
[30] Development of novel therapies for Huntington's disease:hope and challenge
Zheng-hong QIN~(2
~3Laboratory of Cellular Neurobiology
~4Molecular Neurogenetics Unit
Acta Pharmacologica Sinica, 2005, (02) : 129 - 142

← 1 2 3 4 5 →